Previous 10 | Next 10 |
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) There are no approved oral or non-invasive tre...
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) 90 patients completed enrollment across 11 c...
2023-06-30 16:09:14 ET Shares of Belite Bio (NASDAQ: BLTE) were up more than 26% for the week as of Friday's close after rising as much as 35.7%, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech company's stock closed last week at...
2023-06-26 12:52:19 ET Gainers: Benitec Biopharma ( BNTC ) +76% . MoonLake Immunotherapeutics ( MLTX ) +68% . Paltalk ( PALT ) +27% . Whole Earth Brands ( FREE ) +26% . Shengfeng Development Limited ( SFWL ) +26% . Belite Bio...
2023-06-15 12:34:14 ET Summary BLTE works with retinal disease patients. Their lead asset has positive phase 1 data. Their cash position and trial patient population are two worries. Belite Bio ( BLTE ) is a small company with multiple phase 3 trials targeting re...
2023-05-31 12:22:53 ET Shares of Belite Bio (NASDAQ: BLTE) were down 38% Wednesday morning after the clinical-stage biopharmaceutical company said it planned to do an underwritten public stock offering. The company specializes on therapies to treat blindness, diabetes, and liver dis...
2023-05-31 10:05:20 ET Gainers: Marker Therapeutics ( MRKR ) +34% . Nano-X Imaging ( NNOX ) +13% . Zai Lab ( ZLAB ) +9% . Invivyd ( IVVD ) +8% . Corbus Pharmaceuticals ( CRBP ) +7% . Losers: Belite Bio ( BLTE ) ...
2023-05-31 08:32:12 ET Belite Bio ( BLTE ) -37% commences public offering of American Depositary Shares of $30M. Advance Auto Parts ( AAP ) -27% after Q1 earning release . Ambarella ( AMBA ) -20% after Q1 earning release . FG Financial Group (FG...
2023-05-31 03:01:56 ET Belite Bio ( NASDAQ: BLTE ) slumps 38% as it prices an underwritten public offering of 2M ADSs , each representing one of its ordinary shares, and warrants to purchase 2M ordinary shares represented by ADSs, at a public offering price of $15.00 per ADS...
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have si...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata...
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...